Clinical trial
Study of Pemetrexed and Bevacizumab in Patients With Head and Neck Cancer
NCT00222729 · University of Pittsburgh, Other · Completed
Key facts
| NCT number | NCT00222729 |
|---|---|
| Title | Study of Pemetrexed and Bevacizumab in Patients With Head and Neck Cancer |
| Official title | Phase II Trial of Pemetrexed and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer |
| Lead sponsor | University of Pittsburgh, Other |
| Collaborators | Eli Lilly and Company Industry Genentech, Inc. |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug |
| Interventions | Pemetrexed, Bevacizumab |
| Enrollment | 42 |
| Start date | Nov 1, 2005 |
| Primary completion | Oct 1, 2013 |
| Completion | Oct 1, 2013 |
| First posted | Sep 22, 2005 |
| Last update posted | Feb 15, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: